U.S. pharmaceutical innovation has been disproportionately funded by U.S. consumers of patented drugs.
Innovative new medicines can have a profound impact on the health and wellbeing of those stricken with illness. Unfortunately, Canadians are often denied these benefits for months, if not years, while they wait for their government to approve drugs already deemed safe and effective by regulators in the European Union and United States. Smarter regulation could save resources, reduce patient suffering, and improve the lives of Canadians.
New medicines are a central component of modern medical care, treating illness effectively, providing more comfortable treatment regimes, extending life and reducing disability, and sometimes offering new treatment options where none previously existed. However, these benefits come with the potential for harm, which is why governments around the world regulate access to new medicines.
In the wake of the Idle No More protests that have blocked railway lines and have hinted at more mischief, multiple grievances have been advanced in place of clear-headed analyses. But none of the slogans, clichés and guilt-tripping get to the bottom of why some Aboriginals, especially on reserves, are in a sorry state.
First, some misinformation about one supposed reason for the protests, that reserves will be broken up by Bill C-45, should be debunked.
That recent federal legislation allows First Nations to lease some of their land to others if they so choose.
Question: Should patients in Rome or Detroit have faster access to new prescription drugs than someone living in Victoria or Windsor? If your answer to that is no, then here is another query: Why do government agencies tasked to approve or deny new drugs in Europe and the United States (and which presumably have the same high standards as Canada) act quicker when compared to Health Canada?